DX-88 and HAE: a developmental perspective.
An example of an approach to the developmental philosophy of novel recombinant products is explored by using the exemplar of Hereditary Angioedema (HAE). Plasma kallikrein is believed to be an important mediator of angioedema in patients with genetic deficiency of C1 esterase inhibitor (HAE patients). DX-88, a novel Kunitz domain produced by phage display (a powerful method of generating novel binders to potentially therapeutic targets), is a potent and selective inhibitor of plasma kallikrein which in early clinical studies demonstrates a useful efficacy/safety ratio in the treatment of acute attacks of HAE.
Dyax Inc, 300 Technology Square, Cambridge, MA 02139, USA. twilliams@dyax.com
Anthony
A
Williams
Lynn G
LG
Baird
D000208:Acute Disease; D000799:Angioedema / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors* / Q000097:blood; D008297:Male; D019151:Peptide Library; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000627:therapeutic use*
D003174:Complement C1 Inactivator Proteins; D019151:Peptide Library; D011994:Recombinant Proteins; D007610:Kallikreins